RxDoctor Payments Data

Edward Harback, MD

Cardiovascular Disease · West Orange, NJNPI 1720075070

Payments from drug & device makers

$3,346in general payments, 2019–2025

Across 211 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$815
  • Amgen$531
  • Pfizer$289
  • Johnson & Johnson$281
  • AstraZeneca$157
  • Merck$140
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,346 in reported general payments places this provider in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$302,741
Medicare patients
1,029
Services billed
4,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$88,042
EntrestoSacubitril/Valsartan39$54,046
XareltoRivaroxaban28$35,971
JardianceEmpagliflozin21$25,548
Ezetimibe78$1,775
Rosuvastatin Calcium103$1,349
Carvedilol92$1,212
Metoprolol Succinate59$1,173
Valsartan15$1,015
Atorvastatin Calcium81$1,010
Amlodipine Besylate111$977
Verapamil ErVerapamil Hcl15$827
Nebivolol Hcl22$770
Losartan Potassium73$562
ClopidogrelClopidogrel Bisulfate28$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$289$88,04283 claims
NovartisEntresto$815$54,04639 claims
Johnson & JohnsonXarelto$281$35,97128 claims
Boehringer IngelheimJardiance$46$25,54821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →